Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Neveen Bassaly

Internal Medicine Fall River, MA Medical Doctor

NPI 1649274911 CMS profile 29548

277 Pleasant St, Ste 307, Fall River, MA 02721

Open in the dashboard

General payments

$3,812

201 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Neveen Bassaly of Fall River, MA is reported in the CMS Open Payments database as having received $3,812 across 201 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $362 20
2024 General $579 31
2023 General $609 29
2022 General $852 30
2021 General $655 39
2020 General $274 20
2019 General $481 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Neveen Bassaly
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Neveen Bassaly were reported at $362. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Neveen Bassaly Internal Medicine median Middle half National median
2019 $481 $159 $48–$570 $163
2020 $274 $119 $33–$402 $114
2021 $655 $135 $37–$521 $132
2022 $852 $141 $42–$496 $149
2023 $609 $149 $45–$519 $160
2024 $579 $154 $47–$537 $164
2025 $362 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $491 26 payments
  2. Pfizer Inc. $468 33 payments
  3. AbbVie, Inc. $447 20 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $335 15 payments
  5. Vanda Pharmaceuticals Inc. $291 14 payments
  6. Otsuka America Pharmaceutical, Inc. $261 12 payments
  7. Novo Nordisk Inc $237 15 payments
  8. Janssen Pharmaceuticals, Inc $222 3 payments
  9. Lilly USA, LLC $220 13 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $105 5 payments
  11. Other $734 45 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,785 199 payments
  2. Education $27 2 payments
Products named General payments · program years 2019–2025
  1. ELIQUIS $384 27 payments
  2. Kerendia $335 15 payments
  3. UBRELVY $306 14 payments
  4. HETLIOZ $272 13 payments
  5. REXULTI $261 12 payments
  6. XARELTO $222 3 payments
  7. COLOGUARD DNA CAPTURE REAGENTS $219 14 payments
  8. QULIPTA $164 7 payments
  9. FARXIGA $164 8 payments
  10. Ozempic $155 10 payments
  11. Other $2,339 143 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 126 drugs

Part D claims

9,350

Median for Internal Medicine: 777

Drug cost

$585,381

Median for Internal Medicine: $73,373

Branded share of claims

15.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 109 $131,140
Eliquis Apixaban Brand 136 $126,260
Trulicity Dulaglutide Brand 63 $66,794
Januvia Sitagliptin Phosphate Brand 30 $38,717
Farxiga Dapagliflozin Propanediol Brand 41 $30,280
Linzess Linaclotide Brand 31 $24,038
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 29 $18,975
Jardiance Empagliflozin Brand 19 $18,857
Breo Ellipta Fluticasone/Vilanterol Brand 23 $13,702
Xarelto Rivaroxaban Brand 13 $6,739

The 10 drugs with the highest cost, of 126 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 82 billing codes

Paid by Medicare

$161,175

Medicare's payments for the services billed

Medicare patients

376

Average age 69

Services billed

5,449

263 women, 113 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 42%
Diabetes 32%
Depression 31%
Ischemic heart disease 20%
Chronic kidney disease 18%
COPD 18%
Osteoporosis 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $82
$82 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $53
$53 — —
UBRELVY
  • AbbVie, Inc. $43
$43 — —
QULIPTA
  • AbbVie, Inc. $43
$43 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $40
$40 41 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

201 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record